Key result
Genetic polymorphisms in hemostasis genes, including F13, fibrinogen, ITGB3, and PAI-1, were significantly more frequent in patients with heart failure and type 2 diabetes compared to healthy controls.
Why the study?
The role of genetic markers of hemostasis disorders in CHF with both preserved (HFPEF) and reduced (HFREF) LVEF in patients with DM2 had not been adequately addressed.
Do the frequencies of hemostasis gene polymorphisms differ in patients with heart failure and type 2 diabetes compared to healthy controls?
Observational (n=167)
No
Do the frequencies of hemostasis gene polymorphisms differ in patients with heart failure and type 2 diabetes compared to healthy controls?
Odds Ratio: 7.71 (95% CI 1.86–11.95)
Absolute Event Rate: 53.87% vs 16%
p-value: p=<0.001
Specific genetic polymorphisms in hemostasis and cell adhesion genes are differentially associated with HFpEF and HFrEF in patients with type 2 diabetes, suggesting distinct prothrombotic genetic profiles.
Hypothesis-generating for hemostasis variants in diabetic HF; larger prospective studies needed before any clinical role.
Introduction : The study of the role of genetic markers of hemostasis disorders in CHF with both preserved (HFPEF) and reduced (HFREF) LVEF in patients with DM2 has not been adequately addressed . Methods : We used “ Genetics of Hemostasis ” kits from the company DNA Technology (USA). Amplification was performed in a DT-Prime 5 amplifier (DNA Technology , USA) for the prothrombin and factor V gene polymorphisms. Results: F13 (rs5985) and fibrinogen (rs1800790): they are more common in patients with HFPEF and DM2 than in the control group and in patients with HFREF ; ITGA2 (rs1126643): was less common in the HFPEF group than in the control group; ITGB3 (rs5918) and PAI-1 (rs1799889) rs5918 are more common than in the control group and HFPEF group. Conclusions : We encourage carrying out this type of studies since they are scarce in the regional literature.
No takes yet. Share an insight, caveat, or question.
Gómez et al. (2023) conducted an observational in Heart failure (HFpEF and HFrEF) and type 2 diabetes (n=167). Hemostasis gene polymorphisms (e.g., FGB rs1800790) vs. Healthy controls without heart failure and without diabetes was evaluated on Presence of FGB rs1800790 polymorphism (heterozygous or homozygous risk allele) (OR 7.71, 95% CI 1.86-11.95, p=<0.001). Genetic polymorphisms in hemostasis genes, including F13, fibrinogen, ITGB3, and PAI-1, were significantly more frequent in patients with heart failure and type 2 diabetes compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: